The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab.

被引：0

作者：

Deva, Sanjeev ^{[1
]}

Millward, Michael ^{[2
,3
]}

Friedlander, Michael ^{[4
,5
]}

Gan, Hui K. ^{[6
]}

Hovarth, Lisa G. ^{[7
]}

Lee, Jong-Seok ^{[8
]}

Hill, Andrew ^{[9
]}

Sandhu, Shahneen ^{[10
,11
]}

Liang, Liang ^{[12
]}

Shi, Jingwen ^{[12
]}

Zhang, Yun ^{[12
]}

Shi, Yang ^{[12
]}

Ma, Xiaopeng ^{[12
]}

Wu, Xikun ^{[12
]}

Shen, Zhirong ^{[12
]}

Desai, Jayesh ^{[10
,11
]}

机构：

[1] Auckland City Hosp, Auckland Canc Trials Ctr, Auckland, New Zealand

[2] Linear Clin Res, Canc Trials, Perth, WA, Australia

[3] Univ Western Australia, Perth, WA, Australia

[4] Univ New South Wales, Prince Wales Hosp, Dept Med Oncol, Syndney, NSW, Australia

[5] Univ New South Wales, Prince Wales Clin Sch, Syndney, NSW, Australia

[6] Austin Hlth, Med Oncol Dept, Heidelberg, Vic, Australia

[7] Chris OBrien Lifehouse, Camperdown, NSW, Australia

[8] Seoul Natl Univ, Bundang Hosp, Dept Hematol & Med Oncol, Seongnam Si, South Korea

[9] Tasman Oncol Res Ltd, Southport, Qld, Australia

[10] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[11] Univ Melbourne, Melbourne, Vic, Australia

[12] BeiGene Co Ltd, Beijing, Peoples R China

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB511

引用

页数：2